A Novel Approach to Brain Tumor Therapy
Advisory Board member Tara Morrison, MD, a renowned expert in the treatment of brain cancer, reviews a novel brain tumor therapy.
Brain Cancer
Mechanism of Crizotinib Resistance in Neuroblastoma Suggested
Development of new targeted therapies is needed for the treatment of ALK-positive neuroblastoma, according to researchers.
Pegylated Interferon Delays Progression in Children with Glioma
Low-dose pegylated interferon therapy delays the time to disease progression in children with diffuse intrinsic pontine glioma (DIPG).
Efficacy for Thalidomide, Irinotecan Combo Inadequate for Glioma
Combination chemotherapy including thalidomide and irinotecan is not adequately effective for the treatment of aplastic glioma.
Variant of Glioma Susceptibility Found
A new genetic variant in the TP53 gene predicts susceptibility to the development of gliomas and may shed light on its etiology.
Perifosine Prolongs Survival in Neuroblastoma Patients
Perifosine shows activity against chemoresistant and radioresistant neuroblastoma.
Childhood CT Scans May Triple Risk of Leukemia, Brain Tumors, But Absolute Risk is Low
Children <15 years of age exposed to radiation from two to three CT scans to the head may have triple the risk of developing brain cancer, while five to ten scans can triple the risk of developing leukemia.
Chemotherapy + Radiotherapy Ups Survival in Anaplastic Oligodendroglioma
Patients with anaplastic oligodendroglioma with co-deletion for chromosomes 1p and 19q survive significantly longer after receiving chemotherapy immediately prior to radiotherapy, according to long-term follow-up of a randomized phase 3 study presented at the 2012 American Society of Clinical Oncology Annual Meeting.
No Survival Gains Seen with Nimotuzumab in Glioblastoma but More Study Warranted in Patients with MGMT Nonmethylated Glioblastoma
Nimotuzumab does not improve survival among newly diagnosed glioblastoma patients when added to standard temozolomide chemoradiotherapy, but warrants further study among patients with MGMT nonmethylated glioblastoma, according to a randomized multicenter phase 3 study reported at the 2012 American Society of Clinical Oncology Annual Meeting.
Probability of Long-Term Glioblastoma Survival Assessed
In glioblastoma, surviving for two years linked to favorable conditional probability of survival.
- Loading...
Loading...
Loading... 
Loading...